Heron Therapeutics HRTX

NASDAQ HRTX

$0.34 -0.01 (-3.54%)

As of: Sep 9, 2026 · 3:59 PM EDT

Key Stats

Market Cap63.12 Mn

P/E-7.08

P/S0.42

Div. Yield0.00

Total Debt (Qtr)108.73 Mn

Revenue Growth (1y) (Qtr)1.25

Add ratio to table…

About

Heron Therapeutics, Inc. is a commercial-stage biotechnology company specializing in the development and commercialization of therapeutic innovations designed to improve medical care for acute care and oncology patients. The company leverages advanced science, patented drug delivery technologies, and a focused approach to drug discovery to create products that aim to elevate the standard of care in postoperative pain management and chemotherapy-induced nausea and vomiting.…

The company generates revenue primarily through the sale of its proprietary pharmaceutical products in the United States. Its portfolio includes ZYNRELEF, a dual-acting local anesthetic for postoperative pain; APONVIE, an intravenous formulation for postoperative nausea and vomiting; CINVANTI, an injectable NK1 receptor antagonist for chemotherapy-induced nausea and vomiting; and SUSTOL, an extended-release 5-HT3 receptor antagonist for the same indication. These products are marketed to hospitals, surgical centers, and oncology clinics, with reimbursement supported by Medicare, Medicaid, and private insurers. Revenue is derived from direct sales to specialty distributors and full-line wholesalers, which then supply healthcare providers.

The company operates through the following segments:

Acute Care: This segment focuses on products designed to improve outcomes in surgical settings. ZYNRELEF, the flagship product, is an extended-release local anesthetic that combines bupivacaine and meloxicam to provide up to 72 hours of postoperative pain relief, reducing opioid dependence. APONVIE, another key product, is an intravenous formulation of aprepitant used to prevent postoperative nausea and vomiting. Both products are supported by FDA approvals and clinical studies demonstrating superior efficacy compared to standard treatments.
Oncology Care: This segment targets the prevention of chemotherapy-induced nausea and vomiting, a critical need for cancer patients undergoing treatment. CINVANTI is an intravenous NK1 receptor antagonist that provides acute and delayed nausea and vomiting relief without synthetic surfactants, reducing the risk of hypersensitivity reactions. SUSTOL, an extended-release 5-HT3 receptor antagonist, maintains therapeutic drug levels for up to five days, addressing both acute and delayed phases of nausea and vomiting associated with moderately and highly emetogenic chemotherapy regimens.

Heron Therapeutics holds a competitive position in niche segments of the pharmaceutical market, where its products address specific unmet needs with clinically validated advantages. In postoperative pain management, ZYNRELEF competes with traditional local anesthetics like bupivacaine and ropivacaine, as well as newer alternatives such as EXPAREL and XARACOLL. Its extended-release formulation and opioid-sparing benefits provide a distinct edge, particularly as healthcare systems prioritize non-opioid pain management solutions. In the oncology space, CINVANTI and SUSTOL face competition from established NK1 and 5-HT3 receptor antagonists, including Merck’s EMEND and Helsinn’s AKYNZEO. Heron’s products differentiate themselves through unique formulations, such as CINVANTI’s surfactant-free delivery and SUSTOL’s extended-release mechanism, which enhance patient tolerability and convenience. The company’s proprietary Biochronomer technology further strengthens its competitive moat by enabling sustained drug release with a single administration, a capability not widely available among peers.

The company serves a broad customer base comprising hospitals, ambulatory surgical centers, oncology clinics, and healthcare providers. Its products are distributed through specialty distributors and full-line wholesalers, which resell to the end users, including surgeons, anesthesiologists, oncologists, and pharmacists. Key stakeholders also include managed care organizations, group purchasing organizations, and government payors such as Medicare and Medicaid. While specific customer names are not disclosed, the company’s sales and marketing team engages directly with these entities to drive adoption and secure reimbursement coverage.

Investment Thesis

▲ Bull case

Heron Therapeutics is positioned to capitalize on a significant recovery in elective surgical volumes throughout 2026, as the severe weather disruptions in Q1 were temporary and industry-wide, with March already showing a strong rebound to over $15 million in net sales. The company’s confidence in rescheduling deferred procedures aligns with historical patterns where Q3 and Q4 are peak volume quarters, creating a meaningful tailwind that could drive Acute Care revenue above current expectations. This recovery is further supported by the structural tailwind of the NOPAIN Act, which has streamlined reimbursement for ZYNRELEF across approximately 110 million commercial lives, reducing billing friction and enabling broader adoption beyond surgical bundles. The combination of pent-up demand and improved reimbursement access positions ZYNRELEF for accelerated growth as hospitals clear backlogs and prioritize efficient, non-opioid pain management solutions.
The expansion of the IGNITE 2.0 program to 3,109 accounts—a 38% increase from IGNITE 1.0—creates a scalable structural advantage for ZYNRELEF, with data showing 111% unit growth in targeted accounts during the initial phase. This program, now aligned with CrossLink at nearly 90% focus overlap, ensures dedicated distributor and payer engagement in high-potential institutions, driving deeper penetration within accounts as more surgeons adopt ZYNRELEF into their protocols. Coupled with the planned Q3 2026 sales force expansion targeting geographies with full formulary access, IGNITE participation, and payer coverage, this creates a self-reinforcing cycle of adoption that could significantly outpace current market share projections, particularly as the prefilled syringe formulation advances toward stability data readout in Q1 2027.
APONVIE’s inclusion in the fifth consensus guidelines for postoperative nausea and vomiting (PONV) prophylaxis as an A1-evidence-rated, FDA-approved IV push NK1 antagonist represents an underappreciated catalyst that could drive rapid institutional adoption beyond current traction. The guidelines’ emphasis on multimodal prophylaxis, post-discharge nausea and vomiting (PDNV) prevention, and value-based care metrics—such as a favorable number needed to treat (NNT) of 3.8 for aprepitant-dexamethasone—directly address hospital priorities around reducing readmissions, PACU delays, and nursing burden. With APONVIE already showing 68% year-over-year demand unit growth and P&T approval in 1,903 accounts covering 5.8 million annual procedures, the guidelines’ endorsement could unlock broader uptake in high-risk outpatient and ambulatory settings, especially as value-based models increasingly reward outcomes tied to nausea control.
CINVANTI’s stable 25% market share in a highly volatile NK1 category—where monthly category swings range from -19% to +21%—demonstrates exceptional franchise resilience and customer loyalty, providing a reliable cash flow foundation that the market may be undervaluing. The REIGNITE program’s near-term pipeline of approximately $10 million in new formulary wins at major teaching hospitals, combined with the upcoming Q3 2026 expansion of the dedicated aprepitant sales force (which will promote CINVANTI in a secondary role), positions the product for incremental growth without requiring significant additional investment. This durability in oncology supportive care, coupled with pricing discipline maintained across all products, supports sustained profitability and reduces reliance on volatile new product launches for earnings stability.

Heron Therapeutics is positioned to capitalize on a significant recovery in elective surgical volumes throughout 2026, as the severe weather disruptions in Q1 were temporary and industry-wide, with March already showing a strong rebound to over $15 million in net sales. The company’s confidence in rescheduling deferred procedures aligns with historical patterns where Q3 and Q4 are peak volume quarters, creating a meaningful tailwind that could drive Acute Care revenue above current expectations. This recovery is further supported by the structural tailwind of the NOPAIN Act, which has streamlined reimbursement for ZYNRELEF across approximately 110 million commercial lives, reducing billing friction and enabling broader adoption beyond surgical bundles. The combination of pent-up demand and improved reimbursement access positions ZYNRELEF for accelerated growth as hospitals clear backlogs and prioritize efficient, non-opioid pain management solutions.
The expansion of the IGNITE 2.0 program to 3,109 accounts—a 38% increase from IGNITE 1.0—creates a scalable structural advantage for ZYNRELEF, with data showing 111% unit growth in targeted accounts during the initial phase. This program, now aligned with CrossLink at nearly 90% focus overlap, ensures dedicated distributor and payer engagement in high-potential institutions, driving deeper penetration within accounts as more surgeons adopt ZYNRELEF into their protocols. Coupled with the planned Q3 2026 sales force expansion targeting geographies with full formulary access, IGNITE participation, and payer coverage, this creates a self-reinforcing cycle of adoption that could significantly outpace current market share projections, particularly as the prefilled syringe formulation advances toward stability data readout in Q1 2027.
APONVIE’s inclusion in the fifth consensus guidelines for postoperative nausea and vomiting (PONV) prophylaxis as an A1-evidence-rated, FDA-approved IV push NK1 antagonist represents an underappreciated catalyst that could drive rapid institutional adoption beyond current traction. The guidelines’ emphasis on multimodal prophylaxis, post-discharge nausea and vomiting (PDNV) prevention, and value-based care metrics—such as a favorable number needed to treat (NNT) of 3.8 for aprepitant-dexamethasone—directly address hospital priorities around reducing readmissions, PACU delays, and nursing burden. With APONVIE already showing 68% year-over-year demand unit growth and P&T approval in 1,903 accounts covering 5.8 million annual procedures, the guidelines’ endorsement could unlock broader uptake in high-risk outpatient and ambulatory settings, especially as value-based models increasingly reward outcomes tied to nausea control.
CINVANTI’s stable 25% market share in a highly volatile NK1 category—where monthly category swings range from -19% to +21%—demonstrates exceptional franchise resilience and customer loyalty, providing a reliable cash flow foundation that the market may be undervaluing. The REIGNITE program’s near-term pipeline of approximately $10 million in new formulary wins at major teaching hospitals, combined with the upcoming Q3 2026 expansion of the dedicated aprepitant sales force (which will promote CINVANTI in a secondary role), positions the product for incremental growth without requiring significant additional investment. This durability in oncology supportive care, coupled with pricing discipline maintained across all products, supports sustained profitability and reduces reliance on volatile new product launches for earnings stability.

▼ Bear case

Heron Therapeutics’ gross margin pressure from the secondary CINVANTI supplier—carrying a contractual obligation to produce inventory at roughly 3x the cost per batch—may persist longer than anticipated, delaying the expected return to mid-70% gross margins and potentially undermining profitability despite revenue recovery. While management frames this as temporary, the inventory will work through the system over the next two quarters, and any delays in stabilizing supply chain or unexpected yield issues could prolong margin compression, especially if competitive pressures in CINVANTI force pricing concessions that further erode profitability before the primary supplier is fully reinstated.
The company’s reliance on weather-related rebound as a primary driver for Q2–Q4 recovery assumes timely rescheduling of deferred elective procedures, but there is no evidence that hospitals are prioritizing these cases over new demand or that payer authorization delays won’t create bottlenecks, risking a slower-than-expected ramp in surgical volumes that could leave Q1’s weakness as a more persistent drag on Acute Care performance. Furthermore, the NOPAIN Act’s impact on commercial coverage, while cited as enabling reimbursement outside surgical bundles for 110 million lives, lacks specific data on actual adoption rates or payer contract changes, leaving uncertainty about whether the promised friction reduction is translating into meaningful volume growth or merely administrative ease without commercial traction.
Despite the promising data from IGNITE 1.0 showing 111% unit growth in 2,261 accounts, the expansion to IGNITE 2.0’s 3,109 accounts may dilute focus and reduce per-account effectiveness if the program’s success was driven by intensive, high-touch engagement in the initial cohort, and scaling to a broader base risks replicating the same growth rates without proportional investment in distributor incentives or account-level support, potentially resulting in sublinear returns on the expanded initiative. Additionally, the planned Q3 2026 sales force expansion for both ZYNRELEF and aprepitant-dependent products assumes successful recruitment and ramp-up in a competitive talent market, but any delays or underperformance in hiring could blunt the anticipated tailwind, leaving the company over-reliant on unproven execution risk for its growth outlook achievement of full-year guidance.
APONVIE’s inclusion in the fifth consensus guidelines, while clinically significant, may not translate to rapid commercial adoption due to entrenched inpatient workflows, formulary inertia, and the slow pace of clinical guideline implementation in hospital systems, particularly given that the guidelines recommend prophylaxis for patients with greater than two risk factors—representing roughly half the surgical population—but do not mandate use, leaving adoption dependent on individual institution initiatives that could take years to scale, especially in non-academic or resource-constrained settings where change management is slower and cost-benefit analyses may favor incumbent therapies despite APONVIE’s NNT advantage.

Heron Therapeutics’ gross margin pressure from the secondary CINVANTI supplier—carrying a contractual obligation to produce inventory at roughly 3x the cost per batch—may persist longer than anticipated, delaying the expected return to mid-70% gross margins and potentially undermining profitability despite revenue recovery. While management frames this as temporary, the inventory will work through the system over the next two quarters, and any delays in stabilizing supply chain or unexpected yield issues could prolong margin compression, especially if competitive pressures in CINVANTI force pricing concessions that further erode profitability before the primary supplier is fully reinstated.
The company’s reliance on weather-related rebound as a primary driver for Q2–Q4 recovery assumes timely rescheduling of deferred elective procedures, but there is no evidence that hospitals are prioritizing these cases over new demand or that payer authorization delays won’t create bottlenecks, risking a slower-than-expected ramp in surgical volumes that could leave Q1’s weakness as a more persistent drag on Acute Care performance. Furthermore, the NOPAIN Act’s impact on commercial coverage, while cited as enabling reimbursement outside surgical bundles for 110 million lives, lacks specific data on actual adoption rates or payer contract changes, leaving uncertainty about whether the promised friction reduction is translating into meaningful volume growth or merely administrative ease without commercial traction.
Despite the promising data from IGNITE 1.0 showing 111% unit growth in 2,261 accounts, the expansion to IGNITE 2.0’s 3,109 accounts may dilute focus and reduce per-account effectiveness if the program’s success was driven by intensive, high-touch engagement in the initial cohort, and scaling to a broader base risks replicating the same growth rates without proportional investment in distributor incentives or account-level support, potentially resulting in sublinear returns on the expanded initiative. Additionally, the planned Q3 2026 sales force expansion for both ZYNRELEF and aprepitant-dependent products assumes successful recruitment and ramp-up in a competitive talent market, but any delays or underperformance in hiring could blunt the anticipated tailwind, leaving the company over-reliant on unproven execution risk for its growth outlook achievement of full-year guidance.
APONVIE’s inclusion in the fifth consensus guidelines, while clinically significant, may not translate to rapid commercial adoption due to entrenched inpatient workflows, formulary inertia, and the slow pace of clinical guideline implementation in hospital systems, particularly given that the guidelines recommend prophylaxis for patients with greater than two risk factors—representing roughly half the surgical population—but do not mandate use, leaving adoption dependent on individual institution initiatives that could take years to scale, especially in non-academic or resource-constrained settings where change management is slower and cost-benefit analyses may favor incumbent therapies despite APONVIE’s NNT advantage.

Product and Service Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	AMGN	Amgen Inc	primary	211.73 Bn	24.22	5.56	62.75 Bn
2	GILD	Gilead Sciences, Inc.	primary	180.92 Bn	-62.49	5.94	28.66 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	primary	132.16 Bn	30.00	10.50	-
4	REGN	Regeneron Pharmaceuticals, Inc.	primary	82.89 Bn	19.15	5.34	1.99 Bn
5	ARGX	Argenx Se	primary	61.41 Bn	35.80	11.75	-
6	MRNA	Moderna, Inc.	primary	53.99 Bn	-17.13	24.23	0.59 Bn
7	ALNY	Alnylam Pharmaceuticals, Inc.	primary	34.48 Bn	44.51	7.18	-
8	BIIB	Biogen Inc.	primary	31.15 Bn	37.32	3.11	8.09 Bn

Heron Therapeutics HRTX

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password